New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
08:10 EDTACST, NEPTAcasti Pharma presents preliminary data on NKPL66
Acasti Pharma (ACST), a Neptune Technologies & Bioressources (NEPT) subsidiary, announces encouraging preliminary clinical data of its "Randomized, Open-Label, Dose-Ranging, Multi-Center Trial to assess the Safety and efficacy of NKPL66 in the treatment of mild-to-high hypertriglyceridemia". In the course of planning the strategy of its phase III clinical development with CaPre, Acasti examined triglycerides data from its Open-label clinical trial.Data from 157 patients who have completed four weeks of treatment with 0.5, 1, 2 or 4 grams of CaPre per day were assessed and CaPre achieved a clinically important and statistically significant triglyceride reduction of up to 23% as compared to standard of care, after only a 4-week treatment. Moreover, a noteworthy trend indicating a dose-response relationship versus standard of care as well as clinically and statistically significant effects of doubling the doses of CaPre were observed. To date, the results of this preliminary analysis suggest that CaPre is safe and effective for the treatment of patients with triglyceride levels ranging from 200 to 500 mg/dL.
News For ACST;NEPT From The Last 14 Days
Check below for free stories on ACST;NEPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
10:11 EDTNEPTNeptune Technologies receives USPTO patent
Reference Link
July 15, 2014
17:56 EDTNEPTNeptune Technologies reports Q1 revenue C$3.64M vs. C$6.08M last year
Gross profit as a percent of revenue was 14% for the current quarter, versus 10% for the corresponding prior year quarter. Reports Q1 Adjusted EBITDA (C$3.77M) vs. (C$2.7M) in the prior year. Reports Q1 net loss (C$5.7M) vs. (C$3.38M) last year.
July 9, 2014
11:24 EDTNEPTHigh option volume stocks
High option volume stocks: GIMO NEPT BPOP AVAV CBSO LL BOBE KWK GNC TCS
08:08 EDTACSTAcasti Pharma completes Phase II TRIFECTA, Pharmacokinetic trials
Acasti Pharma announces the completion of two trials, the Phase II double-blind, placebo-controlled, or TRIFECTA, study and the Pharmacokinetic trial. The primary objective of the TRIFECTA trial is to evaluate the safety and efficacy of CaPre in reducing triglyceride levels in patients with mild to severe hypertriglyceridemia. Given that the stopping threshold had been met, the data review committee members recommended that there was sufficient evidence of a treatment effect that warranted the termination of the study. The corporation intends to unblind the study and top-line results are expected by the end of September, with full data coming out in the following quarter. Acasti's Pharmacokinetic trial is designed to evaluate blood profiles and bioavailability in healthy human volunteers taking single and multiple doses of Capre. Top-line results are expected to be available by the end of September, with full data coming out in the following quarter.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use